Lindsey James, PhD, is well-suited to the collaborative relationship between UNC Lineberger and UNC Eshelman School of Pharmacy, taking her interests in medicinal chemistry and epigenetics and working with cancer center physicians and researchers to make strides into cancer care and treatment.
UNC Lineberger’s Channing Der, PhD, Sarah Graham Kenan Distinguished Professor in the UNC School of Medicine Department of Pharmacology, was co-corresponding author of a paper published in Cancer Discovery. Antje Schaefer, PhD, research assistant professor in the UNC School of Medicine Department of Pharmacology, was co-first author. In the study, researchers identified a new potential … Continued
The North Carolina Biotechnology Center awarded $100,000 to UNC Lineberger Comprehensive Cancer Center’s Chad Pecot, MD, to study an experimental treatment that would silence a gene commonly mutated in cancer. Using a Nobel Prize-winning technology called RNA interference or RNAi, Pecot’s lab designed an investigational drug to shut down the mutated version of the KRAS … Continued
The KRAS gene is commonly mutated in cancer. In the journal Cancer Discovery, researchers led by Channing Der, PhD, and Aaron Hobbs, PhD, reported details of the role of the KRAS G12R mutation in pancreatic cancer, and therapeutic strategies that might work for this mutation type. By studying unique differences in DNA mutations within the same gene, researchers are working to uncover the mutation-specific mechanisms that drive cancerous growth.
The NCI has awarded more than $1.68 million across five years to UNC Lineberger’s Lindsey James, PhD, to study a gene that can control how other genes are expressed in cells, and when dysregulated, can lead to cancer.